by John A. Jenkins | Dec 3, 2025 | FOIA, Short-Selling, Stock Market
FOIAengine: “Cassandra Unchained” Plays to Fear and Greed Michael Burry, the reclusive contrarian who foresaw the 2007 subprime collapse and became the reluctant hero of The Big Short, has walked away from professional money management for the second — and perhaps...
by John A. Jenkins | May 14, 2025 | FOIA, Law Firms, Litigation, Politics, Short-Selling, Stock Market
FOIAengine Tracks the High Cost of Getting Even, and the Rewards Until six weeks ago, Jason Galanis was Inmate 80739-198 at the federal prison in Montgomery, Alabama, sentenced to almost 16 years confinement after admitting to a wild scheme in which he swindled tens...
by John A. Jenkins | Aug 14, 2024 | FOIA, Litigation, News Media, SEC, Short-Selling
FOIAengine: How the “Bounty Hunter of Wall Street” Hedged His Bets As a young man, Andrew Left was a “real serious kid” – and very religious. He wanted to be a rabbi. But then, in his telling, Left saw a newspaper ad that said, “Earn $100,000.” “I thought, ‘Yeah,...
by Randy E. Miller | Mar 27, 2024 | FDA, FOIA, Hedge Funds, Law Firms, Litigation, Non-Profits, Pharmaceuticals, Politics, Short-Selling, Stock Market
FOIAengine: Conservative Activists, Law Firms, Non-Profits Signal Competing Agendas A review of the most recent Freedom of Information Act requests made to the Food and Drug Administration illustrates how political organizations, law firms, news media, and financial...
by John A. Jenkins | Mar 6, 2024 | FOIA, Litigation, Short-Selling, Stock Market
FOIAengine Previews an April Fool’s Day Courtrooom Grudge Match This week’s story is about two litigation magnets. One is a household name whose lawsuit against OpenAI dominated the news a few days ago. That would be Elon Musk. The other – Aaron Greenspan –...
by Randy E. Miller | Feb 14, 2024 | FDA, FOIA, Hedge Funds, Litigation, Pharmaceuticals, Short-Selling, Stock Market
FOIAengine Breaks Down the Action Financial firms are continuing to monitor many of the pharmaceutical manufacturers we’ve reported on in recent months, including Krystal Biotech, Apellis Pharmaceuticals, Establishment Labs, Catalent and Astellas. That’s according to...
